Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition

Shannon L. Risacher, Noelia Fandos, Judith Romero, Ian Sherriff, P. Pesini, Andrew Saykin, Liana G. Apostolova

Research output: Contribution to journalArticle

Abstract

Introduction: We investigated the relationship of plasma amyloid beta (Aβ) with cerebral deposition of Aβ and tau on positron emission tomography (PET). Methods: Forty-four participants (18 cognitively normal older adults [CN], 10 mild cognitive impairment, 16 Alzheimer's disease [AD]) underwent amyloid PET and a blood draw. Free and total plasma Aβ40 and Aβ42 were assessed using a validated assay. Thirty-seven participants (17 CN, 8 mild cognitive impairment, 12 AD) also underwent a [18F]flortaucipir scan. Scans were preprocessed by standard techniques, and mean global and regional amyloid and tau values were extracted. Free Aβ42/Aβ40 (Aβ F42:F40) and total Aβ42/Aβ40 (Aβ T42:T40) were evaluated for differences by diagnosis and relation to PET Aβ positivity. Relationships between these measures and cerebral Aβ and tau on both regional and voxel-wise basis were also evaluated. Results: Lower Aβ T42:T40 was associated with diagnosis and PET Aβ positivity. Lower plasma Aβ T42:T40 ratios predicted cerebral Aβ positivity, both across the full sample and in CN only. Finally, lower plasma Aβ T42:T40 ratios were associated with increased cortical Aβ and tau in AD-related regions on both regional and voxel-wise analyses. Discussion: Plasma Aβ measures may be useful biomarkers for predicting cerebral Aβ and tau. Additional studies in larger samples are warranted.

Original languageEnglish (US)
Pages (from-to)510-519
Number of pages10
JournalAlzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Volume11
DOIs
StatePublished - Dec 1 2019

Fingerprint

Amyloid
Positron-Emission Tomography
Alzheimer Disease
Biomarkers
Cognitive Dysfunction

Keywords

  • Alzheimer's disease (AD)
  • Amyloid positron emission tomography (PET)
  • Blood biomarkers
  • mild cognitive impairment (MCI)
  • Tau positron emission tomography (PET)

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition. / Risacher, Shannon L.; Fandos, Noelia; Romero, Judith; Sherriff, Ian; Pesini, P.; Saykin, Andrew; Apostolova, Liana G.

In: Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 11, 01.12.2019, p. 510-519.

Research output: Contribution to journalArticle

Risacher, Shannon L. ; Fandos, Noelia ; Romero, Judith ; Sherriff, Ian ; Pesini, P. ; Saykin, Andrew ; Apostolova, Liana G. / Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition. In: Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring. 2019 ; Vol. 11. pp. 510-519.
@article{f7c0bce37cc64a69a93a124931ee53fe,
title = "Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition",
abstract = "Introduction: We investigated the relationship of plasma amyloid beta (Aβ) with cerebral deposition of Aβ and tau on positron emission tomography (PET). Methods: Forty-four participants (18 cognitively normal older adults [CN], 10 mild cognitive impairment, 16 Alzheimer's disease [AD]) underwent amyloid PET and a blood draw. Free and total plasma Aβ40 and Aβ42 were assessed using a validated assay. Thirty-seven participants (17 CN, 8 mild cognitive impairment, 12 AD) also underwent a [18F]flortaucipir scan. Scans were preprocessed by standard techniques, and mean global and regional amyloid and tau values were extracted. Free Aβ42/Aβ40 (Aβ F42:F40) and total Aβ42/Aβ40 (Aβ T42:T40) were evaluated for differences by diagnosis and relation to PET Aβ positivity. Relationships between these measures and cerebral Aβ and tau on both regional and voxel-wise basis were also evaluated. Results: Lower Aβ T42:T40 was associated with diagnosis and PET Aβ positivity. Lower plasma Aβ T42:T40 ratios predicted cerebral Aβ positivity, both across the full sample and in CN only. Finally, lower plasma Aβ T42:T40 ratios were associated with increased cortical Aβ and tau in AD-related regions on both regional and voxel-wise analyses. Discussion: Plasma Aβ measures may be useful biomarkers for predicting cerebral Aβ and tau. Additional studies in larger samples are warranted.",
keywords = "Alzheimer's disease (AD), Amyloid positron emission tomography (PET), Blood biomarkers, mild cognitive impairment (MCI), Tau positron emission tomography (PET)",
author = "Risacher, {Shannon L.} and Noelia Fandos and Judith Romero and Ian Sherriff and P. Pesini and Andrew Saykin and Apostolova, {Liana G.}",
year = "2019",
month = "12",
day = "1",
doi = "10.1016/j.dadm.2019.05.007",
language = "English (US)",
volume = "11",
pages = "510--519",
journal = "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring",
issn = "2352-8729",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition

AU - Risacher, Shannon L.

AU - Fandos, Noelia

AU - Romero, Judith

AU - Sherriff, Ian

AU - Pesini, P.

AU - Saykin, Andrew

AU - Apostolova, Liana G.

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Introduction: We investigated the relationship of plasma amyloid beta (Aβ) with cerebral deposition of Aβ and tau on positron emission tomography (PET). Methods: Forty-four participants (18 cognitively normal older adults [CN], 10 mild cognitive impairment, 16 Alzheimer's disease [AD]) underwent amyloid PET and a blood draw. Free and total plasma Aβ40 and Aβ42 were assessed using a validated assay. Thirty-seven participants (17 CN, 8 mild cognitive impairment, 12 AD) also underwent a [18F]flortaucipir scan. Scans were preprocessed by standard techniques, and mean global and regional amyloid and tau values were extracted. Free Aβ42/Aβ40 (Aβ F42:F40) and total Aβ42/Aβ40 (Aβ T42:T40) were evaluated for differences by diagnosis and relation to PET Aβ positivity. Relationships between these measures and cerebral Aβ and tau on both regional and voxel-wise basis were also evaluated. Results: Lower Aβ T42:T40 was associated with diagnosis and PET Aβ positivity. Lower plasma Aβ T42:T40 ratios predicted cerebral Aβ positivity, both across the full sample and in CN only. Finally, lower plasma Aβ T42:T40 ratios were associated with increased cortical Aβ and tau in AD-related regions on both regional and voxel-wise analyses. Discussion: Plasma Aβ measures may be useful biomarkers for predicting cerebral Aβ and tau. Additional studies in larger samples are warranted.

AB - Introduction: We investigated the relationship of plasma amyloid beta (Aβ) with cerebral deposition of Aβ and tau on positron emission tomography (PET). Methods: Forty-four participants (18 cognitively normal older adults [CN], 10 mild cognitive impairment, 16 Alzheimer's disease [AD]) underwent amyloid PET and a blood draw. Free and total plasma Aβ40 and Aβ42 were assessed using a validated assay. Thirty-seven participants (17 CN, 8 mild cognitive impairment, 12 AD) also underwent a [18F]flortaucipir scan. Scans were preprocessed by standard techniques, and mean global and regional amyloid and tau values were extracted. Free Aβ42/Aβ40 (Aβ F42:F40) and total Aβ42/Aβ40 (Aβ T42:T40) were evaluated for differences by diagnosis and relation to PET Aβ positivity. Relationships between these measures and cerebral Aβ and tau on both regional and voxel-wise basis were also evaluated. Results: Lower Aβ T42:T40 was associated with diagnosis and PET Aβ positivity. Lower plasma Aβ T42:T40 ratios predicted cerebral Aβ positivity, both across the full sample and in CN only. Finally, lower plasma Aβ T42:T40 ratios were associated with increased cortical Aβ and tau in AD-related regions on both regional and voxel-wise analyses. Discussion: Plasma Aβ measures may be useful biomarkers for predicting cerebral Aβ and tau. Additional studies in larger samples are warranted.

KW - Alzheimer's disease (AD)

KW - Amyloid positron emission tomography (PET)

KW - Blood biomarkers

KW - mild cognitive impairment (MCI)

KW - Tau positron emission tomography (PET)

UR - http://www.scopus.com/inward/record.url?scp=85069727958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069727958&partnerID=8YFLogxK

U2 - 10.1016/j.dadm.2019.05.007

DO - 10.1016/j.dadm.2019.05.007

M3 - Article

VL - 11

SP - 510

EP - 519

JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

SN - 2352-8729

ER -